These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22271478)

  • 41. Breast cancer risk reduction therapy: the low-hanging fruit.
    Bevers TB
    J Natl Compr Canc Netw; 2015 Apr; 13(4):376-8. PubMed ID: 25870373
    [No Abstract]   [Full Text] [Related]  

  • 42. Long-term insurance for breast cancer survivors.
    Johns Hopkins Med Lett Health After 50; 2004 Apr; 16(2):3, 7. PubMed ID: 15088564
    [No Abstract]   [Full Text] [Related]  

  • 43. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Breast cancer studies challenge tamoxifen therapy.
    Timms B
    Lancet Oncol; 2000 Nov; 1():132. PubMed ID: 11905647
    [No Abstract]   [Full Text] [Related]  

  • 45. Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer.
    Burstein HJ
    N Engl J Med; 2003 Nov; 349(19):1857-9. PubMed ID: 14551340
    [No Abstract]   [Full Text] [Related]  

  • 46. Letrozole: advancing hormone therapy in breast cancer.
    Lee RJ; Armstrong AC; Wardley AM
    Womens Health (Lond); 2012 Nov; 8(6):611-8. PubMed ID: 23181527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ERBB2 status and outcome of endocrine treatment.
    Miller WR
    Lancet Oncol; 2008 Jan; 9(1):4-5. PubMed ID: 18177812
    [No Abstract]   [Full Text] [Related]  

  • 48. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
    Gamucci T
    Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201
    [No Abstract]   [Full Text] [Related]  

  • 49. Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains.
    Hershman DL
    N Engl J Med; 2015 Jan; 372(5):477-8. PubMed ID: 25495491
    [No Abstract]   [Full Text] [Related]  

  • 50. [Aromatase inhibitors in the treatment of breast cancer].
    Perey L
    Rev Med Suisse Romande; 2000 Jun; 120(6):495-500. PubMed ID: 11014093
    [No Abstract]   [Full Text] [Related]  

  • 51. [Problems and future direction of preoperative systemic therapy for patients with operable breast cancer].
    Zhang B
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):877-80. PubMed ID: 19173839
    [No Abstract]   [Full Text] [Related]  

  • 52. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 10 years of ATAC: one question answered, many others unresolved.
    Gnant M
    Lancet Oncol; 2010 Dec; 11(12):1109-10. PubMed ID: 21126683
    [No Abstract]   [Full Text] [Related]  

  • 55. Anastrozole data show continued delay in relapse, but no clear survival advantage.
    Travis K
    J Natl Cancer Inst; 2005 Jan; 97(2):86-7. PubMed ID: 15657334
    [No Abstract]   [Full Text] [Related]  

  • 56. ATAC trial update.
    Del Mastro L; Venturini M
    Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811447
    [No Abstract]   [Full Text] [Related]  

  • 57. Obesity and hormone therapy in breast cancer: an unfinished puzzle.
    Goodwin PJ; Pritchard KI
    J Clin Oncol; 2010 Jul; 28(21):3405-7. PubMed ID: 20548001
    [No Abstract]   [Full Text] [Related]  

  • 58. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiaromatase agents: evolving role in adjuvant therapy.
    Jones SE
    Clin Breast Cancer; 2002 Apr; 3(1):33-42. PubMed ID: 12020394
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
    Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.